Home » Mergers and Acquisitions Have Failed to Build Value for Pharma, Report Finds
Mergers and Acquisitions Have Failed to Build Value for Pharma, Report Finds
During the past decade large pharmaceutical companies have pursued an aggressive strategy of mergers and acquisition in an effort to grow their businesses. But an analysis from Burrill & Company suggests the approach has been a failure as these companies have seen the loss of $1 trillion in value during the past decade.
On December 31, 2000 the combined market capitalization of 17 of the industry's most active acquirers was $1.57 trillion, excluding Johnson & Johnson. By December 31, 2010 that figure had shrunk to $1.04 trillion, a loss of more than $500 billion in market value. When the combined value of the acquisitions these companies completed during this time -- $425 billion -- is added, close to a trillion dollars in value has been lost during the last decade, even without taking into account transactions of less than $10 million.
The findings are contained within Biotech 2011-Life Sciences: Looking Back to See Ahead, Burrill & Company's 25th annual report on the biotech industry. The book is now available in print and electronic format at www.burrillandco.com/resources.html.
"The loss of revenue the leading pharmaceutical companies are looking at over the next several years does not just reflect the impact of competition from generic drugs, but also the failure of Big Pharma's research and development to generate innovative products to replace those going off patent," says G. Steven Burrill, CEO of the San Francisco-based merchant bank Burrill & Company. "If the industry is to return to the type of growth it once enjoyed, it must innovate its way out of its current predicament."
Big Pharma's R&D productivity has steadily fallen as the industry continues to produce roughly the same number of new drugs each year despite a steady increase in R&D investment. At the same time, smaller companies have produced a growing share of new drugs and done so more cost effectively.
Pharmaceutical companies today are pursuing acquisitions of innovative biotech products and companies, but are now taking steps to leave in place the culture of these companies to protect the innovation they covet. In other instances, Big Pharma is seeking to emulate biotechs through new R&D models that create small, focused, independent research units that operate much like biotechs.
This is one of the many issues explored in Biotech 2011-Life Sciences: Looking Back to See Ahead. Other sections of the book consider healthcare reform, the transformation to personalized medicine, regulation and policy reshaping the industry, development in industrial and agricultural biotechnology, the changing financing environment, and the growing importance of emerging economies within the industry.
Merck Stops Development of Parkinson’s DrugFrom Bloomberg
Merck & Co. will end development of preladenant because a preliminary review of late-stage clinical trials suggests it doesn’t work
French Drugmaker on Trial for Suspected DeathsFrom Yahoo! News
Servier Laboratories, French drugmaker responsible for producing diabetes and weight loss drug Mediator, faces charges for deception in relation to the suspected deaths of hundreds of people.
Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online
Novo A/S has acquired Xellia Pharmaceuticals of Norway
Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online
Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
- All news »